This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Macular Disorders  • Retinal/ Chorioretinal Disorders  • Ophthalmological Procedures, Other  • Randomized Controlled Trial  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

The Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study Report 6

The SCORE Study Research Group^*

Arch Ophthalmol. 2009;127(9):1115-1128.

Objective  To compare the efficacy and safety of 1-mg and 4-mg doses of preservative-free intravitreal triamcinolone with standard care (grid photocoagulation in eyes without dense macular hemorrhage and deferral of photocoagulation until hemorrhage clears in eyes with dense macular hemorrhage) for eyes with vision loss associated with macular edema secondary to branch retinal vein occlusion (BRVO).

Methods  Multicenter, randomized clinical trial of 411 participants.

Main Outcome Measure  Gain in visual acuity letter score of 15 or more from baseline to month 12.

Results  Twenty-nine percent, 26%, and 27% of participants achieved the primary outcome in the standard care, 1-mg, and 4-mg groups, respectively. None of the pairwise comparisons between the 3 groups was statistically significant at month 12. The rates of elevated intraocular pressure and cataract were similar for the standard care and 1-mg groups, but higher in the 4-mg group.

Conclusions  There was no difference identified in visual acuity at 12 months for the standard care group compared with the triamcinolone groups; however, rates of adverse events (particularly elevated intraocular pressure and cataract) were highest in the 4-mg group.

Application to Clinical Practice  Grid photocoagulation as applied in the SCORE Study remains the standard care for patients with vision loss associated with macular edema secondary to BRVO who have characteristics similar to participants in the SCORE-BRVO trial. Grid photocoagulation should remain the benchmark against which other treatments are compared in clinical trials for eyes with vision loss associated with macular edema secondary to BRVO.

Trial Registration  clinicaltrials.gov Identifier: NCT00105027

Authors/Writing Committee: Ingrid U. Scott, MD, MPH (chair); Michael S. Ip, MD; Paul C. VanVeldhuisen, PhD; Neal L. Oden, PhD; Barbara A. Blodi, MD; Marian Fisher, PhD; Clement K. Chan, MD; Victor H. Gonzalez, MD; Lawrence J. Singerman, MD; and Michael Tolentino, MD.
Group Information: A complete list of the SCORE Study Research Group members is published in Arch Ophthalmol. 2009;127(9):1101-1114.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Laser Photocoagulation and Intravitreal Injection of Triamcinolone for Retinal Vein Occlusions
Chew
JAMA 2009;302:1693-1695.
FULL TEXT  

A Randomized Trial Comparing the Efficacy and Safety of Intravitreal Triamcinolone With Observation to Treat Vision Loss Associated With Macular Edema Secondary to Central Retinal Vein Occlusion: The Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study Report 5
The SCORE Study Research Group
Arch Ophthalmol 2009;127:1101-1114.
ABSTRACT | FULL TEXT  

SCOREing in Retinal Venous Occlusive Disease
Apte
Arch Ophthalmol 2009;127:1203-1204.
FULL TEXT